HOME
About the company
Innovation
Investors
Media
Contact
中文  |  EN
HOME
About the company
Innovation
Investors
Media
Contact

Company Overview

With our focus on the health of Chinese patients suffering from ocular diseases, we persist in benefiting ocular patients through various means, and we firmly believe that both inhouse R&D and strategic alliance are vital to the company. ​​
新闻动态 更多
欧康维视治疗累及眼后段慢性非感染性葡萄膜炎产品OT-401(商品名:优施莹)正式获国家药监局批准上市
第7款产品进入III期临床试验!欧康维视OT-703(ILUVIEN)获得III期临床试验批件
梅开二度!欧康维视与晖致再度达成药品推广战略合作,拟出资人民币3,000万元获得爱赛平®独家推广权利
出海之我见!——欧康维视CMO陈冬红博士:天时地利人和,出海时机已成熟!与海外监管机构的沟通很重要!
在研产品
科学的前进 : 致力于打造 药物整体解决方案
欧康责任
守护视觉,还原色彩 不让颜色成为记忆
Can we help you?
​
COPYRIGHT © 2021 Ocumension Therapeutics (Shanghai) Co., Ltd.,
About the company

疾病与研发

Public Disclosure

Media

Contact